Why are online pharmacies the obvious candidates?
The regulatory framework and the inspection findings are addressed elsewhere in this library, in the rules guide and the thematic review analysis. This article assumes that material and addresses the question those pieces deliberately leave open, which is whether an online pharmacy should do it.
Three characteristics make distance-selling pharmacies the natural adopters. They hold volume concentrated in narrow product ranges, since a business built around weight management, hair loss or contraception dispenses a small number of lines many thousands of times, which is precisely the profile automation rewards. They have no counter, so the physical dispensary serves no purpose beyond throughput and can be optimised without regard to patient experience within the building. And they are already remote from the patient, meaning the psychological objection which a community pharmacist feels about a prescription assembled elsewhere does not arise in the same way, since the patient was never going to watch it being dispensed.
Add the operational reality that scaling a dispensary is capital-intensive, slow and constrained by premises, whilst scaling a hub relationship is a contract negotiation, and the attraction is obvious. The remainder of this article is concerned with what the attraction obscures.
What does hub and spoke actually save?
Honestly assessed, less than the pitch suggests and more than the sceptics allow, with the difference determined almost entirely by scale.
The genuine savings are in labour per item, where automated assembly at volume outperforms manual dispensing substantially, in premises, where dispensary space is expensive and a hub converts fixed cost into variable, and in capital avoided, since the automation which produces the labour saving is purchased by someone else.
Set against those are costs which business cases routinely omit. The governance overhead increases rather than decreasing, since the arrangement requires written agreements, oversight arrangements, audit of the hub's performance and the additional records the regulator expects, none of which existed when dispensing happened in one room under one pharmacist. There is margin transferred to the hub, since the hub is a business earning from the arrangement, and the saving is what remains after it has taken its share. There is a transition cost, comprising integration, process redesign and the period during which both models run. And there is the coordination cost of a supply chain with an additional party in it, which surfaces on the days something goes wrong rather than in the model.
The consequence is a threshold effect. Below a certain volume the fixed governance and integration costs exceed the per-item saving, and the arrangement makes a business more complicated without making it cheaper. Above it, the savings compound. Where that threshold sits varies by product mix and by the terms obtained, and any operator who has not calculated it for their own numbers is making the decision on atmosphere.
Does outsourcing dispensing commoditise your business?
Consider what a typical online pharmacy actually performs itself once the arrangement is in place. Payments are handled by an acquirer. Delivery is handled by a carrier. Prescribing is frequently handled by contracted prescribers. The platform is built by an agency. And now dispensing is handled by a hub. What remains inside the business is a brand, a website and a regulatory licence, and the operational capability which distinguished it from a competitor has been contracted out to suppliers that competitor can also engage. The endpoint is a market in which several operators, using the same hub, the same carrier and comparable prescribing capacity, sell the same medicines to the same patients, and compete upon the only dimension left to them, which is price. This is a familiar destination and not a hypothetical one, since the analysis of the oral GLP-1 launch described precisely that dynamic arriving in the largest private category. The decision is therefore not merely operational. A business which differentiates through clinical service, follow-up and trust can outsource assembly without losing what it competes on. A business whose proposition was speed and convenience has just outsourced its proposition.
What happens if your hub fails?
A traditional pharmacy which loses hub access has a dispensary, stock and staff, and reverts to dispensing in-house whilst the difficulty is resolved. The arrangement degrades rather than stopping.
An online pharmacy which has closed its own dispensing capability has none of those things. There is no counter, no meaningful local stock, no automation and frequently no staff who have dispensed at volume for a year. When the hub experiences a system failure, a regulatory intervention, a stock crisis or an insolvency, the business does not degrade. It stops, and it stops for every patient simultaneously, in a model whose entire promise was reliable delivery to the door.
The mitigations are unglamorous and should be contractual rather than aspirational. A service level with meaningful consequences rather than best endeavours. Continuity obligations specifying what happens during hub downtime and who bears the cost. A retained minimum capability, whether a smaller in-house dispensing function or a documented second hub arrangement, accepting that redundancy costs money and is worth what it costs. And notice periods long enough to rebuild, since a hub entitled to terminate at ninety days holds a business which cannot rebuild in ninety days.
Concentration risk is the difference between an operational decision and a strategic one, and it is the reason this article treats the subject as strategy rather than logistics.
Who owns the hub, and what do they learn about you?
A hub dispensing a pharmacy's prescriptions necessarily observes a great deal about that pharmacy. It sees volumes by line, growth rates, seasonality, product mix, average order values, the pace at which a new service scales, and the point at which a competitor's promotion moves demand. That is a clear commercial picture, assembled continuously, and it is generated as a by-product of the service rather than through anything improper.
Whether that matters depends upon who owns the hub. Where the owner is an independent operator with no retail interest, the information is commercially sensitive but not competitively dangerous. Where the owner also operates a pharmacy, a group, or a platform in the same categories, the position is different, and an operator should establish it before signing rather than after noticing.
Three protections are worth negotiating. Confidentiality extending to derived and aggregated data, not merely to patient information, since aggregation is exactly how the picture becomes useful. Restrictions upon internal use for competing purposes, expressed in terms which mean something. And a defined position on what happens at termination, covering what is deleted and what may be retained.
This is not an argument against hub arrangements. It is an argument for reading the counterparty as carefully as the contract, which is the same discipline this library applies to payment partners and to web developers, and for the same reason.
Who does the patient blame?
The pharmacy, always, and this is the point at which the regulatory position and the commercial one converge.
A patient whose parcel is late, whose item is wrong, or whose supply is interrupted does not distinguish between the pharmacy which took the order and the hub which assembled it. Nor should they, since the pharmacy supplied the medicine, holds the professional relationship and appears on the label. The regulator takes the same view of accountability, as the rules guide sets out.
What follows commercially is that a pharmacy outsourcing dispensing has outsourced its control over the experience whilst retaining full ownership of the consequences, and it must therefore invest in the parts it still controls. That means visibility, so that staff answering a query can see the actual status rather than promising to chase the hub. It means authority to resolve, so that the pharmacy can put things right without waiting for a supplier's process. And it means hub performance treated as pharmacy performance within the weekly measures, since the patient experiences one business.
The reviews this produces are the pharmacy's reviews, and as the reviews article notes, they are frequently the first notification of a problem the pharmacy should already have known about.
Can you bring dispensing back in-house?
In principle yes, in practice with considerable difficulty, and the asymmetry deserves stating before rather than after.
Capability atrophies quickly once volume leaves. Premises are surrendered or repurposed. Automation is not bought, then becomes a capital decision at the least convenient moment. Experienced dispensing staff move to employers who dispense. And the operational knowledge of running a dispensary at volume, which is real expertise rather than a procedure, leaves with them.
The result is that a decision presented as an operational choice is frequently, in practice, a one-way door. That is not a reason to refuse it. It is a reason to make it deliberately, with the reversal cost estimated honestly at the point of signature, and with a retained capability if the business judges the dependency intolerable. An operator unable to describe how they would bring dispensing back within six months has not made a reversible decision, whatever the contract says about notice.
What does it do to your valuation?
Both directions, and the net effect depends upon what a purchaser is buying.
It helps where a purchaser values asset-light scalability, predictable unit costs and the absence of capital tied up in premises and automation, and where the arrangement demonstrably works with clean governance.
It harms where diligence identifies supplier concentration without redundancy, a contract terminable on short notice, no evidence of hub oversight, or a business whose margin depends upon terms the purchaser cannot be confident of retaining. A single-supplier dependency for the core operational function is precisely what diligence is designed to surface, and it is priced.
The practical instruction follows. If the business may be sold, the arrangement should be documented, governed and evidenced as though a purchaser's adviser were already reading it, since eventually one will.
When is hub and spoke the right answer?
Stated as this site's opinion, four conditions should hold together rather than individually.
Volume above the threshold, calculated on the business's own numbers rather than the hub's illustration, with the governance overhead included as a cost.
Differentiation that survives, meaning the business competes on clinical service, outcomes or trust rather than on the speed of a parcel, such that outsourcing assembly does not outsource the proposition.
Governance capacity to oversee a supplier, since the arrangement increases the governance burden and the thematic review found that oversight is where operators most commonly fall short.
An honest continuity position, comprising retained capability, a second option or contractual protection genuinely adequate to the risk.
Where all four hold, hub and spoke is a sound decision which frees a business to invest in what actually distinguishes it. Where the attraction is principally that the numbers look difficult and the hub promises to make them easier, the honest reading is that the business has a cost problem which outsourcing will convert into a dependency problem, and dependency problems are considerably harder to reverse.
What should be decided before signing?
Six determinations, each recorded, and none of which the hub's own materials will make for the pharmacy.
The threshold volume at which this pays on our numbers, with governance costed in. What we still compete on once assembly leaves. Who owns this hub, what else they operate, and what protects our commercial information. What happens on the day the hub stops, expressed as a plan rather than a clause. What reversal would cost and how long it would take. And who inside this business owns the oversight, by name, with the authority and time to perform it.
Key takeaways
- Online pharmacies are the natural candidates, holding concentrated volume, standardised ranges, no counter and existing distance from the patient, which is why the decision arrives early and is frequently made on atmosphere.
- Savings are real in labour, premises and avoided capital, offset by increased governance overhead, transferred margin, transition and coordination costs, producing a threshold below which the arrangement complicates without saving.
- The commoditisation risk is the strategic one, since a business which has outsourced payments, delivery, prescribing, platform and now dispensing competes with identical rivals on price alone.
- Concentration risk is higher without a physical fallback, since an online pharmacy losing hub access stops rather than degrades, which makes service levels, continuity terms, retained capability and notice periods strategic rather than administrative.
- A hub necessarily observes volumes, mix, growth and seasonality, so establish who owns it and negotiate confidentiality extending to derived data.
- Patients and the regulator attribute everything to the supplying pharmacy, so invest in visibility, authority to resolve and treating hub performance as pharmacy performance.
- Reversal is far harder than commencement as capability atrophies, and an operator unable to describe bringing dispensing back within six months has made a one-way decision whatever the notice period says.
FAQs
Oversight you can actually evidence.
Outsourcing assembly increases the governance burden rather than reducing it, and the oversight has to be evidenced. Dataforge PMR keeps the patient journey whole across a hub arrangement, so the pharmacy that remains accountable can see status, resolve queries without chasing a supplier, and measure hub performance as its own.
See Dataforge PMR